What's Hot
View all perspectives
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 2 months ago
Knowledge Bowl at #ACR21
⭐️This HLA allele can be seen in a certain vasculitis where panuveitis is a possibility and has a venulitis predilection
➡️HLA B51
@RheumNow
Janet Pope Janetbirdope
3 years 2 months ago
If you need a #knee replacement move out of Ontario. More income disparity of access to #TKR in Ontario vs Pennsylvania. Lack of universal #healthcare in 🇨🇦. Oh Canada we fail. @RheumNow #ACR21 abst#1037 https://t.co/kobUlT3Ugr
TheDaoIndex KDAO2011
3 years 2 months ago
Novel way to treat inflammatory arthritis!
A bioengineered probiotic bacterium, L. reuteri (LrS235) was found effective to reduce inflammation and clinical signs of inflammation in rats with inflammatory arthritis.
Abst # 1707 #ACR21 @rheumnow https://t.co/UC28yRlGYP
TheDaoIndex KDAO2011
3 years 2 months ago
"Baseline and routine EKGS are NOT required for SLE patients just because they are on HCQ!" - Dr. HM Belmont. "The drug has been demonized due to its use in COVID patients. We don't need to hold HCQ for EMR alerts (e.g, with cipro, SSRIs, etc)." Abstr#1743 #ACR21 @rheumnow https://t.co/5Bxavo6dRg
Meral K. El Ramahi, MD MeralElRamahiMD
3 years 2 months ago
Wager question that cemented the winners: @UTMB:
⭐️This monogenic disease can mimic Behcet's & occurs d/t mutat in TNFAIP3.
➡️Haploinsufficiency A20
Congrats to the winners & all contestants, including the top 2 finalists: @MGHrheumatology & @EmoryUniversity!
#ACR21 @RheumNow https://t.co/LZqsBKiPL8
Aurelie Najm AurelieRheumo
3 years 2 months ago
Anti-NETs antibodies in #COVID.
1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30
2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19
3️⃣ ⬆️ in pts requiring MV
In a study of 328 pts. Probably driving complement activation!
#ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN
Dr. Antoni Chan synovialjoints
3 years 2 months ago
AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0
Robert B Chao, MD doctorRBC
3 years 2 months ago
Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment
⭐️no new onset IBD or exacerbation of IBD
⭐️no uveitis, infections, TB
Abs#1342
#ACR21
@RheumNow
https://t.co/x3OmLgInV0
Aurelie Najm AurelieRheumo
3 years 2 months ago
⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow interview with @ErnestChoy1 is out. Link below
https://t.co/zYb4rXcw1x https://t.co/i39xXnfC3Q
Janet Pope Janetbirdope
3 years 2 months ago
You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person visits. 45 docs in 18 practices comparing in person to virtual. In person wins but not by a large gap! Abst#1448 @dansolomon @RheumNow #ACR21 #ACRBest session today coming up https://t.co/8lcuMW0bwb
Dr. Rachel Tate uptoTate
3 years 2 months ago
SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX
Dr. John Cush RheumNow
3 years 2 months ago
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Poster Hall